A carregar...
Adjuvant Trastuzumab: Does Time Really Matter?
Trastuzumab is now the standard of care for metastatic and early breast cancer; however, questions remain regarding the optimal schedule of trastuzumab in the adjuvant setting. This commentary discusses the results from recent clinical trials with regard to the optimal duration of trastuzumab treatm...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3662838/ https://ncbi.nlm.nih.gov/pubmed/23624497 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0094 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|